Newsroom

Industry News

7 Jul

Baylor Oncology Medical Director Joins Actinium’s (ATNM) Iomab-B Scientific Advisory Board

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of M. Yair Levy, MD of Baylor to its Scientific Advisory Board (SAB) for Iomab™-B. Iomab™-B, the Company’s lead radioimmunotherapy asset,...

Read more

2 Jul

Celator(R) Pharmaceuticals (CPXX) Announces Analyst Day and Webcast

Celator Pharmaceuticals, Inc. CPXX +1.35% , a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the company will host its first Analyst Day on Thursday, July 17, 2014, from 9:00am – 12:00pm ET at the Omni Berkshire Place Hotel in New York City....

Read more

19 Jun

Prima BioMed (PBMD) to Present at 2014 WAGO Annual Meeting

Prima BioMed Ltd (ASX: PRR) (NASDAQ:PBMD) (“Prima”, “the Company”) today advised that the Western Association of Gynecologic Oncologists (WAGO) Program Committee has accepted the abstract entitled “Treatment with Mucin 1-Autologous Dendritic Cell Therapy Significantly Improves Progression-Free Survival in Ovarian Cancer Patients in Second Remission” for oral presentation at the...

Read more

17 Jun

Inovio Pharmaceuticals (INO) Broadens its Intellectual Property Portfolio from the University of Pennsylvania

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies against cancer, infectious diseases and new immune activators. Inovio has an ongoing collaborative research agreement with the university to...

Read more

16 Jun

Arch Therapeutics (ARTH) Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announces that co-founder and inventing scientist Dr....

Read more

16 Jun

Stevia First Corp. Accelerates Commercialization With Launch of SF Pure $STVF

Stevia First Corp. (OTCQB: STVF) (“Stevia First” or the “Company”), an agricultural biotechnology company based in California’s Central Valley growing region and focused on the industrial scale production of stevia, the all-natural zero-calorie sweetener that is rapidly transforming the food and beverage industry, is pleased to announce that it...

Read more

16 Jun

Inovio Pharmaceuticals (INO) to Present at Upcoming Healthcare Conferences

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President & CEO, Dr. J. Joseph Kim, will participate in a panel at the Piper Jaffray GenomeRx Symposium on June 23 to discuss Inovio’s leadership in the advancement of novel DNA-based immune therapies. Inovio management will also present a corporate...

Read more

Page 227 of 234« First...102030...225226227228229...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address